Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The antiemetic, pharmacokinetic, and metabolic profile of CP-99,994, a potent NK1 receptor antagonist, has been carefully evaluated. As a result we began a medicinal chemistry program which initially identified a 3-furanyl analogue (6) with improved antiemetic potency and a methyl sulfone (5) with enhanced metabolic stability and oral bioavailability. The improved pharmacokinetic profile of methyl sulfone (5) was associated with its low lipophilicity, and a therefore a number of heterocyclic analogues with reduced log D were synthesized. Out of this program emerged 19 (GR203040), a tetrazolyl-substituted analogue. Tetrazole 19 inhibits radiation-induced emesis in the ferret with high potency when administered both subcutaneously and orally, has a long duration of action, and has high oral bioavailability in the dog. Tetrazole 19 is currently undergoing evaluation as a novel approach for the control of emesis associated with, for example, cancer chemotherapy.

Type

Journal article

Journal

J Med Chem

Publication Date

22/12/1995

Volume

38

Pages

4985 - 4992

Keywords

Animals, Antiemetics, Biological Availability, CHO Cells, Cell Membrane, Cricetinae, Dogs, Female, Ferrets, Gerbillinae, Magnetic Resonance Spectroscopy, Male, Neurokinin-1 Receptor Antagonists, Piperidines, Tachykinins, Tetrazoles, Vomiting, Whole-Body Irradiation